Clinical trials: Metabolic Dysfunction-Associated Steatohepatitis
Non-Alcoholic Fatty Liver Disease, MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease
Effects of Probiotics (P. Pentosaceus, L. Lactis or L. Helveticus) in NASH
A study for evaluating the improvement effect on Metabolic dysfunction-associated steatotic liver disease (MASLD) of probiotics Metabolic dysfunction-associated steatotic liver disease (MASLD) is associated with dysbiosis of the…
- Trial name
- NCT04555434
- Testing
- Probiotics
- Where
- South Korea
- Volunteers
- 89 people, healthy volunteers welcome
- Sponsor
- Chuncheon Sacred Heart Hospital
Metabolic Dysfunction-Associated Steatotic Liver Disease
Development of Microbial Therapeutics for Metabolic-associated Fatty Liver Disease: From Mechanistic Investigations to Clinical Trials
The goal of this clinical trial is to investigate the efficacy and safety of pasteurized Akkermansia muciniphila strain NTUH_Amuc03 (pAKK NTUH_Amuc03) in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)Patients.
- Trial name
- NCT06873165
- Testing
- Probiotics
- Where
- Taiwan
- Volunteers
- 40 people
- Sponsor
- National Taiwan University Hospital
Metabolic Dysfunction Associated Steatotic Liver Disease, Non-Alcoholic Fatty Liver Disease (NAFLD)
Non-Invasive Diagnostic Tests for MASLD in Pediatric Population
This study aims to test the utility of Velacur ultrasound as a non-invasive, rapid, point of care diagnostic tool for detecting the presence and amount of hepatic steatosis in children and adolescents aged 2 - 20 years.
- Trial name
- NCT06218589
- Testing
- Velacur, MRI, Blood sample collection for biomarkers
- Where
- 2 sites in United States
- Volunteers
- 200 people
- Sponsor
- Emory University
Metabolic Associated Fatty Liver Disease
Supplementation With Alpha-lipoic Acid and Silybum Marianum(LUDLEV®) for the Improvement of Fatty Liver Disease
This randomized, controlled, double-blind study evaluates the utility of alpha-lipoic acid and silybum marianum , versus placebo, in the treatment of metabolic associated fatty liver disease.
- Trial name
- NCT05913986
- Testing
- LUDLEV®300 mg/46.2 mg
- Where
- Mexico
- Volunteers
- 50 people
- Sponsor
- Saluz Investigación S. C.
Type 1 Diabetes, Liver Steatoses
Prevalence and Risk Factors of Metabolic-Associated Hepatic Steatosis in Individuals Living With Type 1 Diabetes
The goal of this observational cross-sectional study is to assess the prevalence and stage of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), specifically liver steatosis and fibrosis in adults aged 18 and older…
- Conditions
- Type 1 Diabetes, Liver Steatoses, MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, Liver Fibrosis
- Trial name
- STEA-DT1 (NCT07475962)
- Testing
- Adiposity and BMI Classification
- Volunteers
- 100 people
- Sponsor
- Institut de Recherches Cliniques de Montreal
Metabolic Dysfunction-associated Fatty Liver Disease
Efficacy and Safety of Calculus Bovis Sativus in Adults With MAFLD
Metabolic dysfunction-associated fatty liver disease (MAFLD) has become the most common chronic liver disease worldwide. Timely therapeutic intervention for MAFLD is crucial for improving patient prognosis and preventing its…
- Trial name
- NCT07085962
- Testing
- Calculus bovis sativus
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Huazhong University of Science and Technology
Intermittent Fasting, Metabolic Dysfunction-Associated Fatty Liver Disease
Intermittent Fasting and Metabolic Dysfunction Associated Fatty Liver Disease
Previous studies have investigated the effect of different dietary patterns on metabolic dysfunction-associated fatty liver disease (MAFLD), for which lifestyle modification remains the primary treatment.
- Trial name
- NCT06664684
- Testing
- Energy-restricted dietary intervention, Energy + time-restricted dietary intervention
- Where
- Turkey (Türkiye)
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- Istanbul Bilgi University
Metabolic Dysfunction-Associated Steatotic Liver Disease, MASLD
Assessment of Non-Invasive Testing in Major Liver-Related Outcomes
This is a general clinical research protocol to study the clinical evaluation, investigation and long-term follow up of patients who have Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and MetALD (MASLD and…
- Conditions
- Metabolic Dysfunction-Associated Steatotic Liver Disease, MASLD, MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, MASLD/MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease / Metabolic Dysfunction-Associated Steatohepatitis)
- Trial name
- MAIL-NIT (NCT06986447)
- Where
- 8 sites in United States
- Volunteers
- 1,689 people
- Sponsor
- HRI-MAIL-NIT
Obesity, Metabolic Dysfunction-associated Steatotic Liver Disease
ELEVATE-LIVER: A Study to Test Whether Survodutide Helps Improve Heart Structure and Function in People With Overweight or Obesity and Fatty Liver Disease
This study is for adults aged 18 years and older who have a type of fatty liver disease called metabolic dysfunction-associated steatotic liver disease (MASLD).
- Trial name
- NCT07850063
- Testing
- Survodutide
- Where
- 25 sites in United States, China and 3 more
- Volunteers
- 600 people
- Sponsor
- Boehringer Ingelheim
Healthy Volunteers, Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
A Trial to Learn if ALN-PNP is Safe and Well Tolerated in Healthy Adults and Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
This study is researching an experimental drug called ALN-PNP (called "study drug"). This is a first in human study. The study drug is not approved by any public health agency such as the United States Food and Drug…
- Trial name
- NCT05648214
- Testing
- ALN-PNP
- Where
- 6 sites in United States
- Volunteers
- 172 people, healthy volunteers welcome
- Sponsor
- Regeneron Pharmaceuticals
Fatty Liver
Alpha-Glutathione-S-Transferase (AlphaGST) and MARINA Index in Metabolic-Dysfunction-Associated-Steatotic-Liver-Disease (MASLD)
AlphaGST represents a liver enzyme whose serologic levels progressively increase in alcoholic and viral chronic hepatitis according to the worsening of liver fibrosis.
- Trial name
- NCT05804955
- Where
- Italy
- Volunteers
- 260 people
- Sponsor
- University of Campania Luigi Vanvitelli
Obesity, Liver Diseases
Effect of Endoscopic Sleeve Gastroplasty in Patients With Obesity and MASH: A Randomized Controlled Trial
Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common chronic liver disease globally. While weight loss through lifestyle modification is the standard treatment, most patients regain weight limiting…
- Conditions
- Obesity, Liver Diseases, Liver Fibrosis, Liver Fat
- Trial name
- NCT06138821
- Testing
- ESG + lifestyle modification, Lifestyle modification
- Where
- 2 sites in United States
- Volunteers
- 132 people
- Sponsor
- Pichamol Jirapinyo, MD, MPH
Metabolic Dysfunction-Associated Steatotic Liver Disease, Non-Alcoholic Fatty Liver Disease
Impact of Overt and Subclinical Hypothyroidism on Liver Fibrosis in Patients With MASLD
Metabolic dysfunction-associated steatotic liver disease (MASLD), previously known as non-alcoholic fatty liver disease (NAFLD), is one of the most common chronic liver conditions globally.
- Conditions
- Metabolic Dysfunction-Associated Steatotic Liver Disease, Non-Alcoholic Fatty Liver Disease, Hypothyroidism, Liver Fibrosis
- Trial name
- NCT07827430
- Volunteers
- 120 people
- Sponsor
- Assiut University
MASH-related HCC
Long Term Prediction of MASH-related HCC Risk by Proteomics
MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease), affects over 25% of the global population and is increasingly associated with obesity and type 2 diabetes.
- Trial name
- PROTEOMASH (NCT07332611)
- Testing
- Proteomics
- Where
- France
- Volunteers
- 30 people
- Sponsor
- University Hospital, Bordeaux
Fatty Liver Disease, Type 2 Diabetes
Effect of Intermittent Calorie Restriction on MASLD Patients With Abnormal Glucose Metabolism
This study is designed to observe the effect of 5:2 intermittent calorie restriction (fasting 2 days each week) on liver fat content in MASLD patients with abnormal blood glucose.
- Conditions
- Fatty Liver Disease, Type 2 Diabetes, Impaired Glucose Regulation
- Trial name
- NCT04283942
- Testing
- Intermittent calorie restriction (ICR), Continuous calorie restriction (CCR)
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Shanghai Zhongshan Hospital
Metabolic Dysfunction-Associated Fatty Liver Disease, Obesity, Adolescent
Effect of L-citrulline and HIIT on Arterial Stiffness, Body Composition, and Lipid Profile in Adolescents with Steatosis Associated with Metabolic Dysfunction (MASLD)
Obesity and metabolic dysfunction-associated steatotic liver disease (MASLD) accelerate the appearance of arterial stiffness due to inflammatory and oxidative stress mechanisms producing increased vascular tone and increasing the…
- Conditions
- Metabolic Dysfunction-Associated Fatty Liver Disease, Obesity, Adolescent, Arterial Stiffness
- Trial name
- NCT05778266
- Testing
- L-citrulline, Carboxymethyl cellulose, High Intensity Intervals Training
- Where
- Mexico
- Volunteers
- 43 people
- Sponsor
- Universidad de Guanajuato
NAFLD
Rutin and Vitamin C in Patients With Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD)
evaluate the combined effects of Rutin and Vitamin C versus Vitamin C alone on selected oxidative stress markers, inflammation, hepatic steatosis regression, and associated metabolic parameters in patients with MASLD
- Trial name
- NCT07310407
- Testing
- Rutin + Vitamin C, Vitamin C 500mg, Lifestyle Intervention
- Where
- Egypt
- Volunteers
- 120 people
- Sponsor
- Ain Shams University
Metabolic Dysfunction-Associated Steatotic Liver Disease, Liver Fibrosis
Automated Passive Case-Finding for Advanced Liver Fibrosis in MASLD: The LiverSeek Programme
LiverSeek is a fully automated, passive case-finding programme for advanced liver fibrosis associated with metabolic dysfunction-associated steatotic liver disease (MASLD) in primary care.
- Conditions
- Metabolic Dysfunction-Associated Steatotic Liver Disease, Liver Fibrosis, Non-alcoholic Fatty Liver Disease NAFLD, Type 2 Diabetes Mellitus
- Trial name
- LiverSeek (NCT07658755)
- Where
- Spain
- Volunteers
- 3,000 people
- Sponsor
- Hospital General Universitario Gregorio Marañon
Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD), Hepatomegaly
Gepaktiv vs UDCA and Ademetionine in MAFLD With Hepatomegaly
This study compares the effectiveness of the dietary supplement Gepaktiv with standard medications (UDCA and Ademetionine) in patients with fatty liver disease (MAFLD) and liver enlargement (hepatomegaly).
- Conditions
- Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD), Hepatomegaly, Nonalcoholic Fatty Liver (NAFL), Nonalcoholic Fatty Liver Disease (NAFLD)
- Trial name
- HEPACT (NCT07068191)
- Testing
- Dietary supplement "Gepaktiv", UDCA (Ursodeoxycholic acid), Ademetionine
- Where
- Russia
- Volunteers
- 90 people
- Sponsor
- Phenomen Pharma
Metabolic Dysfunction-associated Steatotic Liver Disease
Digital Pathology and AI for Liver Outcomes in MASLD
The aim of this multi-center, retrospective epidemiologic study is to confirm the prognostic performance of the Digital Pathology (DP) FibroNest Phenotypic Fibrosis Composite Score (Ph-FCS), derived from standard digital…
- Trial name
- DPAILO-1 (NCT06344364)
- Testing
- Digital Pathology FibroNest Phenotypic Fibrosis Composite Score (Ph-FCS)
- Where
- 3 sites in Hong Kong, Spain
- Volunteers
- 1,241 people
- Sponsor
- PharmaNest, Inc